CTKB — Cytek Biosciences Balance Sheet
0.000.00%
Last trade - 00:00
- $774.48m
- $514.28m
- $193.02m
- 79
- 22
- 72
- 59
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 30.1 | 165 | 365 | 341 | 262 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 17.7 | 18.1 | 29.6 | 50.9 | 56.1 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 67.8 | 209 | 432 | 454 | 392 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.04 | 2.14 | 5.85 | 27.6 | 29.3 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 70.4 | 220 | 463 | 519 | 494 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 21 | 26.5 | 33.2 | 49 | 56.2 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 37.4 | 41.7 | 58.3 | 94.2 | 101 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 33 | 178 | 405 | 425 | 393 |
Total Liabilities & Shareholders' Equity | 70.4 | 220 | 463 | 519 | 494 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |